Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Clinical Therapeutics
|
June 9, 2016
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective
Lee J Smolen, James C Gahn, Ghaith Mitri, et al.
Journal of Medical Economics
|
November 5, 2015
Febuxostat in the management of gout: a cost-effectiveness analysis
Lee J Smolen, James C Gahn, Ghaith Mitri, et al.
BMC Musculoskeletal Disorders
|
November 1, 2012
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
Daniel R Murphy, Lee J Smolen, Timothy M Klein, et al.
Health Services Research
|
February 14, 2013
Using common random numbers in health care cost-effectiveness simulation modeling
Daniel R Murphy, Robert W Klein, Lee J Smolen, et al.
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists
|
December 19, 2014
Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting
Elizabeth L Eby, Lee J Smolen, Amber C Pitts, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
May 22, 2012
Budget impact analysis of insulin therapies and associated delivery systems
Lauren J Lee, Lee J Smolen, Timothy M Klein, et al.
Journal of Medical Economics
|
July 29, 2010
Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial
Robert L Ohsfeldt, Sanjay K Gandhi, Lee J Smolen, et al.
Current Medical Research and Opinion
|
January 27, 2011
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
Nicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, et al.
Cost Effectiveness and Resource Allocation : C/E
|
April 9, 2009
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
Nicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, et al.
Journal of Medical Economics
|
February 7, 2012
Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States
Haya Ascher-Svanum, Nicolas M Furiak, Anthony H Lawson, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Clinical Therapeutics
|
June 9, 2016
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective
Lee J Smolen, James C Gahn, Ghaith Mitri, et al.
Journal of Medical Economics
|
November 5, 2015
Febuxostat in the management of gout: a cost-effectiveness analysis
Lee J Smolen, James C Gahn, Ghaith Mitri, et al.
BMC Musculoskeletal Disorders
|
November 1, 2012
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
Daniel R Murphy, Lee J Smolen, Timothy M Klein, et al.
Health Services Research
|
February 14, 2013
Using common random numbers in health care cost-effectiveness simulation modeling
Daniel R Murphy, Robert W Klein, Lee J Smolen, et al.
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists
|
December 19, 2014
Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting
Elizabeth L Eby, Lee J Smolen, Amber C Pitts, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
May 22, 2012
Budget impact analysis of insulin therapies and associated delivery systems
Lauren J Lee, Lee J Smolen, Timothy M Klein, et al.
Journal of Medical Economics
|
July 29, 2010
Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial
Robert L Ohsfeldt, Sanjay K Gandhi, Lee J Smolen, et al.
Current Medical Research and Opinion
|
January 27, 2011
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
Nicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, et al.
Cost Effectiveness and Resource Allocation : C/E
|
April 9, 2009
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
Nicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, et al.
Journal of Medical Economics
|
February 7, 2012
Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States
Haya Ascher-Svanum, Nicolas M Furiak, Anthony H Lawson, et al.
Page
of 2